NasdaqGM:RLAYBiotechs
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib
Relay Therapeutics, Inc. recently reported full-year 2025 results, with revenue rising to US$15.36 million from US$10.01 million and its net loss narrowing to US$276.48 million from US$337.71 million, while also securing FDA Breakthrough Therapy designation and advancing multiple 2026 data milestones for lead asset zovegalisib.
Alongside a narrower basic loss per share of US$1.61 versus US$2.36 a year earlier, the company filed a US$96.18 million common-stock shelf registration tied to an...